Amlodipine Medreg

Quick links to important sections

Amlodipine Medreg

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlodipine Medreg

Quick Facts

Property Description
Active Ingredient Amlodipine (INN)
Form Oral Tablet
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
Common Use Managing high blood pressure
Origin Synthetic (Chemically manufactured)

What Type of Medicine is Amlodipine Medreg?

Amlodipine Medreg is a prescription-only medication whose active ingredient, Amlodipine, belongs to a class of drugs known as calcium channel blockers (CCBs). This classification defines its fundamental therapeutic action in the body. Amlodipine is a synthetic, single-ingredient product and its effectiveness in treating hypertension and angina is clinically recognized.

It is specifically a dihydropyridine type of calcium channel blocker, a subclass known for its potent vascular action.

What is the Composition and Form?

The primary component of Amlodipine Medreg is the active substance Amlodipine, which is commonly formulated as Amlodipine besylate. The product is most commonly presented as an oral tablet, the standard dosage form used for long-term chronic medication management. The specific formulation ensures controlled release of the active ingredient for a consistent therapeutic effect. In addition to Amlodipine, the tablets contain various inactive ingredients, or excipients, which are necessary for the pill’s structure and stability.

What is Amlodipine's Main Purpose?

The general purpose of Amlodipine is to help relieve tension in the circulatory system by promoting the relaxation and widening of the blood vessels. This fundamental action allows blood to flow more easily through the arteries, which helps to lower high blood pressure (acting as an antihypertensive). Furthermore, Amlodipine is used to decrease the frequency of chest pain, fulfilling its role as an antianginal agent.

Regulatory References

  1. World Health Organization
  2. U.S. National Library of Medicine (MedlinePlus)

What side effects are possible with Amlodipine Medreg?

Possible side effects and safety information

The safety profile for Amlodipine Medreg is structured by classifying documented adverse reactions according to frequency and the physiological systems affected, based strictly on official regulatory labeling.

Official Adverse Reaction Categories

Adverse effects are documented across various System-Organ Classes, including Nervous System, Cardiac, Vascular, and Gastrointestinal Disorders, among others.

Frequency Classification Examples (as documented in regulatory sources)
Common (ge 1/100) Edema (Swelling of hands/ankles), Headache, Dizziness, Somnolence, Palpitations, Nausea, Abdominal pain, Flushing, Fatigue.
Uncommon (ge 1/1,000) Hypotension, Insomnia, Mood changes, Tremor, Arrhythmia, Vomiting, Rash, Muscle cramps, Weight increase/decrease.
Very Rare (<1/10,000) Angioedema, Erythema multiforme, Hepatitis, Jaundice, Myocardial infarction, Leukocytopenia, Hyperglycaemia.

Serious Safety Considerations

The official safety data identifies certain rare but clinically significant adverse events. These include severe hypersensitivity reactions such as Angioedema, as well as documented risks of very rare hepatic disorders (Hepatitis, Jaundice). Furthermore, regulatory labels note that worsening angina and acute myocardial infarction have been documented in patients, particularly upon the initiation or increase of the amlodipine dose.

Population and Contextual Safety Notes

The most common adverse reaction, edema, is documented as being dose-related. Additionally, common effects like headache and somnolence are specifically noted to occur at the beginning of treatment. Specific caution and a potential need for a lower initial dose are required for older adults and individuals with hepatic impairment, where the medicine's clearance is decreased. Contraindications include severe hypotension and cardiogenic shock, as defined in the official prescribing information.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Amlodipine Medreg is primarily characterized by profound and prolonged systemic hypotension resulting from excessive peripheral vasodilation, which is the key mechanism of toxicity. Documented clinical signs may include dizziness, somnolence, and disturbances in heart rhythm, which can manifest as either tachycardia or bradycardia. Due to the sustained nature of these effects, the official documentation cites a risk of potentially life-threatening outcomes, including shock and cardiovascular collapse. Specific patient groups, such as the elderly and those with impaired hepatic function, may exhibit prolonged effects due to slower drug clearance.

When to Seek Urgent Medical Help

Regulatory guidance mandates that individuals with a suspected overdose seek immediate medical attention by contacting emergency services. This urgent action is required if symptoms include collapse, seizure, or difficulty breathing. Because the drug has a long elimination half-life, a period of prolonged hospital monitoring and continuous cardiac assessment is necessary, even if initial symptoms appear mild.

Official Management Measures

Treatment for overdose is symptomatic and supportive, as no specific antidote is known. Supportive care documented in regulatory prescribing information includes measures such as administering activated charcoal to limit absorption in early cases. Severe hypotension requires active cardiovascular support, which may involve the use of intravenous calcium and vasopressors.

Therapeutic Uses of Amlodipine Medreg

What Amlodipine Medreg Treats: Main Uses and Benefits

Amlodipine Medreg is used to help manage symptoms and effects associated with certain cardiovascular conditions, including high blood pressure (hypertension) and specific types of chest pain. It is an approved treatment that assists the body's natural processes. This action supports the functioning of the heart.

This medication is indicated for conditions including hypertension, chronic stable angina (recurring chest pain), and vasospastic angina (also known as Prinzmetal's or variant angina). For patients with certain types of coronary artery disease, it may be used as part of a treatment plan to support overall heart health. The primary therapeutic purpose is assistance in managing blood pressure and relieving chest pain symptoms.


Quick Fact: Relief for Angina (Chest Pain)

Eligibility and Restrictions for Use

Amlodipine Medreg is approved for use in adults for the treatment of hypertension and specific types of angina. It is also approved for pediatric patients aged 6 to 17 years for hypertension, though doses exceeding 5 mg daily have not been studied in this group. The safety and efficacy of Amlodipine have not been established in children under 6 years of age.


Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with known hypersensitivity or allergy to Amlodipine, any other dihydropyridine derivative, or any component of the formulation. Absolute exclusion also applies to patients in a state of severe hypotension, cardiogenic shock, or with obstruction of the left ventricular outflow tract (such as high-grade aortic stenosis).


Condition-Based Restrictions

Population Regulatory Status
Severe Hepatic Impairment Restricted use; requires a cautious approach and slow titration due to altered drug clearance.
Older Adults (Geriatric Use) Use is permitted, but dosage increase must be done with care and may require a lower initial amount.
Renal Impairment No initial dosage adjustment is required, as the degree of impairment is not correlated with plasma concentrations.

Pregnancy and Lactation

Use during pregnancy is advised only if the potential benefit outweighs the potential risk, as safety in human pregnancy is not established. Use is not recommended during breastfeeding due to the drug being excreted in human milk, and the effect on the nursing infant is unknown.

What should I know about interactions with other medicines?

Amlodipine Medreg’s interaction profile is primarily defined by the way co-administered substances alter drug exposure or produce additive effects, all as stated in regulatory labeling.

Interaction Types

The most critical interactions are linked to the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, or certain HIV protease inhibitors) is officially documented to increase Amlodipine plasma exposure. Conversely, combining it with strong CYP3A4 inducers (like rifampicin or Apalutamide) may decrease Amlodipine concentrations.

Pharmacodynamic interactions are also noted. Co-administration with other antihypertensive agents may result in an additive blood pressure lowering effect.

Restrictions and Cautions

A formal interaction-related restriction is documented with Simvastatin. Amlodipine can substantially increase Simvastatin plasma concentrations; consequently, regulatory labeling mandates that the Simvastatin dose must not exceed 20 mg daily when co-administered.

Consumption of grapefruit or grapefruit juice is documented to increase Amlodipine concentration. Official studies documented no significant pharmacokinetic interactions with Digoxin, Warfarin, or Atorvastatin.

Two population-specific interaction cautions are officially noted: the effects of CYP3A4 inhibitors are more pronounced in elderly patients, and patients with hepatic impairment exhibit decreased Amlodipine clearance, increasing overall exposure.

Mechanism of Action

The mechanism of Amlodipine is defined by its selective action as a calcium ion influx inhibitor (blocker) on L-type voltage-dependent calcium channels (CaV1.2). These channels are primarily targeted in the membranes of vascular smooth muscle cells within peripheral arteries. The binding of Amlodipine to the dihydropyridine site physically prevents the influx of extracellular calcium ions, which are essential for initiating muscle contraction.

The resulting inhibition of calcium entry prevents the smooth muscle from fully contracting, thereby inducing vasodilation (widening of the arteries). This systemic arterial relaxation reduces the overall Total Peripheral Vascular Resistance (PVR), a mechanical force within the systemic circulation. This reduction in PVR is the core physiological consequence, reducing afterload on the heart. A distinct feature of the drug's mechanism is the gradual rate of association and dissociation with the channel, which contributes to a sustained, consistent modulation of vascular tone across the dosing interval.

Dosage and Administration Information

How to Use Amlodipine Medreg

The administration of Amlodipine is defined by specific instructions concerning route, schedule, and dosage. This medicine is prescribed for long-term, chronic management and its usage is structured around consistent daily intake to achieve stable medicine levels in the bloodstream, typically reached after 7 to 8 days.


Administration Protocol and Dosing Ranges

Feature Instruction
Route of Administration Oral administration, available as tablets, oral solution, and powder for solution.
Dosing Schedule Once daily. Adults typically start at 5 mg daily, with a maximum dose of 10 mg daily for both hypertension and angina.
Timing in Relation to Meals May be taken with or without food. Administration should occur at the same time each day for consistency.
Dose Titration Period Dosage adjustment (titration) is generally recommended to proceed over 7 to 14 days to fully assess the response to a given dose level.

Specific Use Conditions

Specialized instructions govern use in specific populations and with certain intake factors:

  • Pediatric (6–17 years) Dosing: The prescribed dose for hypertension in this age group ranges from 2.5 mg to 5 mg once daily; doses exceeding 5 mg have not been studied.
  • Population Adjustments: A lower initial dose of 2.5 mg once daily is often specified for small, fragile, or elderly patients, and those with hepatic impairment, due to a potentially reduced clearance of the medicine. Normal dosage is recommended for patients with renal impairment.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible, unless it is 12 hours or less before the next scheduled dose, in which case the missed dose should be skipped.
  • Beverage Constraint: Use with grapefruit or grapefruit juice is not recommended as this may increase the availability of the medicine.

These instructions define the standardized procedures for taking the medicine, focusing on consistency and dose adjustment timing.

Recent Clinical Evidence

Amlodipine Medreg: Recent Clinical Evidence


Early-Phase Clinical Trials

Initial research explored whether the drug affects clinical outcomes and evaluated pain reduction in small patient cohorts. These Phase 1 and Phase 2 trials focused primarily on exploring the effects across various dose levels and collecting data on how the body handles the drug. Specific studies evaluated changes in certain biological measures (biomarkers). Data from these early stages informed the design of later-phase studies.


Phase 3 Efficacy Trials

  • Primary Outcome Assessment Multiple Phase 3 randomized, controlled trials (RCTs) assessed the primary endpoint of symptom control over a 12-week period. The changes in symptom severity observed in these trials were examined to understand the drug’s role in managing the condition. Analysis involved comparing the group receiving the drug to the group receiving a placebo or an active comparator.

  • Long-Term Follow-up Extended trials, following patient groups for up to one year, were conducted to gather additional data on effects over time and safety. These studies did not have a pre-specified primary endpoint but were designed to collect observational data. They explored how symptoms and quality of life measures changed over the full duration of the research period.


Combination Therapy Studies

Research was evaluated regarding the use of the drug alongside standard-of-care treatments for patients with more severe disease. This approach was studied to assess potential outcomes after initial treatment failure. Studies focused on changes in disease activity scores and the incidence of adverse events when both treatments were used together. These findings were collected for use in planning later research on multidrug regimens.


Safety and Tolerability Profile

Detailed safety data was collected across all clinical stages. Common and serious adverse events were tracked and documented. Evidence for safety and tolerability was collected during long-term use assessment. Overall, the research evaluated the drug against placebo in terms of the frequency and type of side effects observed. The data is available in the full clinical trial reports.

Key Studies & References

  1. Amlodipine - StatPearls - NCBI Bookshelf (Review of Indications and Trials)
  2. Amlodipine 10mg Drug Use Investigation (ENTER10) (NCT01252563) - ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Amlodipine Medreg (FAQ)

Q: Is Amlodipine Medreg the same as a blood thinner or anticoagulant?

A: Amlodipine Medreg is classified as a calcium channel blocker (CCB), which works by relaxing and widening blood vessels. It is not classified as a blood thinner or anticoagulant, as its primary action is not to prevent blood clotting.

Q: Is Amlodipine Medreg prescribed for children?

A: Official prescribing information indicates that this medicine is approved for the treatment of high blood pressure (hypertension) in pediatric patients aged 6 years and older. Official prescribing documents define the specific populations and dose ranges that have been studied.

Q: Why is Amlodipine Medreg taken only once a day?

A: Amlodipine is a long-acting medicine characterized by a slow absorption rate and a long terminal half-life. This long duration of action supports consistent effectiveness over 24 hours, leading to a once-daily dosing schedule.

Q: Does Amlodipine Medreg start working immediately after the first dose?

A: The medicine begins to gradually reduce blood pressure within approximately 4 to 8 hours after taking the first dose. Due to the gradual onset of action, acute or sudden symptomatic hypotension (a severe drop in blood pressure) is described as unlikely in the official labeling.

Q: How long does Amlodipine Medreg take to reach its full effect?

A: Consistent blood levels are generally reached after taking the medicine for 7 to 8 consecutive days. Official information indicates that the full therapeutic effect on blood pressure control is typically attained within two weeks after starting the medicine or adjusting the dose.

Q: What is the mechanism by which Amlodipine Medreg works to reduce chest pain?

A: The antianginal effects are thought to work by reducing the resistance the heart pumps against (afterload), which decreases the heart muscle's demand for oxygen. It also helps block spasm in the coronary arteries, which is beneficial for vasospastic angina.

Q: Does Amlodipine Medreg affect a person's ability to exercise?

A: Clinical studies documented that for patients with chronic stable angina, Amlodipine increased symptom-limited exercise time. This means research found a change in the amount of time patients could exercise before experiencing angina symptoms.

Q: Is it safe to stop taking Amlodipine Medreg suddenly?

A: Official information advises patients not to stop taking the medicine suddenly without consulting their healthcare provider. Sudden discontinuation may be associated with a risk of an exacerbation, or worsening, of angina symptoms.

Q: Does Amlodipine Medreg lose its effect over time with long-term use?

A: Clinical pharmacology data confirms that the antihypertensive effectiveness of Amlodipine is maintained for at least 24 hours during chronic, once-daily use. The drug is formulated for sustained efficacy over time.

Q: How long does Amlodipine Medreg stay in the body after stopping use?

A: Amlodipine is characterized by a long elimination half-life, which is approximately 30 to 50 hours. The half-life describes the time it takes for the body to fully clear the medicine from the bloodstream after discontinuation.

Q: Is it common to experience swollen ankles or feet when taking Amlodipine Medreg?

A: Swelling, particularly of the hands, feet, or ankles (edema), is documented as the most common adverse reaction associated with this medicine. Official information also notes that the occurrence of swelling is often linked to the dose.

Q: Will side effects like headache or dizziness eventually go away after starting Amlodipine Medreg?

A: The official safety notes indicate that common effects such as headache and somnolence (drowsiness) occur specifically at the beginning of treatment. As such, these reactions may lessen as the body adjusts to the medicine.

Q: Can Amlodipine Medreg cause fatigue or general tiredness?

A: Fatigue (excessive tiredness) and somnolence (drowsiness) are documented in regulatory labeling as common adverse reactions. These effects are often noted in the official labeling as occurring at the beginning of treatment.

Q: Can Amlodipine Medreg cause a feeling of flushing or warmth in the face and neck?

A: Flushing, which is a temporary feeling of warmth or redness, is listed as a common adverse reaction in the official product information. This effect is a known result of the drug's mechanism of widening blood vessels.

Q: Is it possible for Amlodipine Medreg to cause palpitations or a pounding heartbeat?

A: Palpitations (an unusually strong or rapid awareness of the heartbeat) are listed as a common adverse reaction, which is documented in clinical studies as part of the medicine's safety profile.

Q: Is weight gain a potential side effect of Amlodipine Medreg?

A: Both weight increase and weight decrease are documented in official labeling as uncommon adverse reactions. Weight fluctuations, especially increases, are sometimes related to fluid retention which causes edema.

Q: Is there a risk of developing low blood pressure (hypotension) with Amlodipine Medreg?

A: Low blood pressure (hypotension) is listed as a potential adverse reaction. Because the onset of action is gradual, acute or sudden symptomatic hypotension is described as unlikely in the official labeling.

Q: Can Amlodipine Medreg cause changes in vision?

A: Visual disturbance is documented in the official product information as a common adverse reaction. Any changes in vision are important to note and can be discussed with a healthcare professional.

Q: Can Amlodipine Medreg affect sleep or cause insomnia?

A: Insomnia (difficulty falling or staying asleep) is documented in the official product information as an uncommon adverse reaction. This effect is part of the medicine’s established safety profile.

Q: Is Amlodipine Medreg known to cause or worsen muscle cramps?

A: Muscle cramps are documented in official product information as an uncommon adverse reaction associated with the use of this medicine. This information is based on collected clinical data.

Q: Is there any information about Amlodipine Medreg being associated with hair loss?

A: Alopecia (hair loss) is reported in postmarketing experience as an uncommon adverse reaction. This type of effect is tracked by regulators after the medicine becomes widely available.

Q: Does Amlodipine Medreg cause issues with gums or dental health?

A: Official postmarketing safety data has included reports of gingival hyperplasia, which is the enlargement of the gums. This specific dental effect has been noted as a potential adverse reaction.

Q: Does Amlodipine Medreg have a potential to affect blood sugar levels?

A: Official regulatory labeling includes hyperglycemia, or high blood sugar, as a very rare adverse reaction. Any notable change in blood sugar is part of the ongoing monitoring advised when taking this medicine.

Q: Does Amlodipine Medreg have an effect on heart rate?

A: While adverse reactions like palpitations and arrhythmia are documented, clinical data notes that the medicine generally is not accompanied by a significant change in heart rate during chronic dosing. A small increase in cardiac performance has been noted in studies.

Q: Does Amlodipine Medreg have any known effects on kidney function?

A: The medicine’s clearance is not significantly affected by renal impairment. As a result, official prescribing documents state that no initial dosage adjustment is required for patients with pre-existing kidney conditions.

Q: Does Amlodipine Medreg have a long-term safety profile?

A: Long-term clinical trials have been conducted to gather safety data over extended periods of use. Specific caution is documented regarding its use in patients with severe heart failure, as studies have shown a potentially increased risk of pulmonary edema in this population.

Q: Is Amlodipine Medreg used for conditions other than high blood pressure and angina?

A: Official indications (approved uses) for Amlodipine include the treatment of high blood pressure and certain types of angina. It is also indicated for the symptomatic management of chronic stable angina in the context of coronary artery disease.

Q: Are there any herbal or dietary supplements that are known to interact with Amlodipine Medreg?

A: Official medical information has specifically noted that the herbal remedy St John's wort is thought to affect the way Amlodipine works in the body. For information on other specific supplements, regulatory documents often advise discussing potential supplement use with a healthcare professional.

Q: Why is Amlodipine Medreg sometimes combined with a statin in a single pill?

A: Combination products (like those with a statin or another medicine) are often used to increase patient convenience by allowing multiple necessary medicines to be taken in a single tablet, which supports long-term treatment.

How should Amlodipine Medreg be stored and disposed of?

How to Store and Dispose of Amlodipine Tablets

The storage and disposal of Amlodipine tablets must adhere strictly to the conditions specified in official product labeling to maintain effectiveness and ensure safety.


Official Storage Conditions

Amlodipine tablets must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). It is essential to protect the tablets from light and moisture by keeping the medication in the tightly closed, original container.

Additionally, the medication must be stored out of the sight and reach of children to prevent accidental ingestion. Do not use the tablets beyond the expiration date listed on the package.


Disposal Requirements

Unused or expired Amlodipine must be disposed of in accordance with local pharmaceutical requirements.

Do not dispose of the medication via household waste or wastewater (flushing down the toilet or pouring down the sink) as this helps to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlodipine Medreg found in:

A-Z Index: